 Home > Medical News > Latest Medical News > Ascent Pharmaceuticals MDM2-p53 inhibitor APG-115 obtained Fast Track qualification from the US FDA for the treatment of relapsed/refractory unresectable/metastatic melanoma

Ascent Pharmaceuticals MDM2-p53 inhibitor APG-115 obtained Fast Track qualification from the US FDA for the treatment of relapsed/refractory unresectable/metastatic melanoma

 Last Update: 2021-09-30
 Source: Internet
 Author: User

Tags

opening new business

chemistry research

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Suzhou, China and Rockville, Maryland, U.

Melanoma is a potentially fatal malignant tumor, and its incidence continues to rise throughout the world

The FTD award is based on the results of APG-115's preclinical research and preliminary clinical data from an ongoing phase II clinical trial (APG-115-US-002, NCT03611868)

FTD aims to accelerate the development and rapid review of drugs for serious diseases in order to solve the serious unmet clinical medical needs in key areas

Dr.

references

About APG-115

APG-115 is an oral, highly selective, small-molecule MDM2 inhibitor independently developed by Yasheng Pharmaceutical.

About Yasheng Pharmaceutical

Ascent Pharmaceuticals is an original innovative drug research and development company based in China and facing the world in the clinical development stage.

Ascent Pharmaceuticals has a self-constructed protein-protein interaction targeted drug design platform, and is at the forefront of new drug development in the apoptosis pathway in the world

Relying on strong R&D capabilities, Yasheng Pharmaceuticals has deployed intellectual property rights worldwide, and has cooperated with leading biotechnology and pharmaceutical companies such as UNITY, MD Anderson, Mayo Medical Center, Dana-Farber Cancer Institute, Merck, AstraZeneca, etc.

Forward-looking statement

The forward-looking statements made in this article only relate to events or information as of the date when the statement is made in this article

Source: Yasheng Pharmaceutical

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.